The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-11 and is reviewed periodically as new material appears.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
The revolts culminated with the revolt in East Germany against the Marxist–Leninist regime of Erich Honecker and demands for the Berlin Wall to be torn down. The event in East Germany developed into a popular mass revolt with sections of the Berlin Wall being torn down and East and West Berliners uniting. Gorbachev's refusal to use Soviet forces based in East Germany to suppress the revolt was seen as a sign that the Cold War had ended. Honecker was pressured to resign from office and the new government committed itself to reunification with West Germany. The Marxist–Leninist regime of Nicolae Ceaușescu in Romania was forcefully overthrown in 1989 and Ceaușescu was executed. Almost Eastern Bloc regimes also fell during the Revolutions of 1989 (1988–1993). Unrest and eventual collapse of Marxism–Leninism also occurred in Yugoslavia, although for different reasons than those of the Warsaw Pact. The death of Josip Broz Tito in 1980 and the subsequent vacuum of strong leadership amidst an economic crisis allowed the rise of rival ethnic nationalism in the multinational country. The first leader to exploit such nationalism for political purposes was Slobodan Milošević, who used it to seize power as president of Serbia and demanded concessions to Serbia and Serbs by the other republics in the Yugoslav federation.
=== Neuronal proliferation === NGF can drive the expression of genes such as bcl-2 by binding to the Tropomyosin receptor kinase A, which stimulates the proliferation and survival of the target neuron. High affinity binding between proNGF, sortilin, and p75NTR can result in either survival or programmed cell death (PCD). Study results indicate that superior cervical ganglia neurons that express both p75NTR and TrkA die when treated with proNGF, while NGF treatment of these same neurons results in survival and axonal growth. Survival and PCD mechanisms are mediated through adaptor protein binding to the death domain of the p75NTR cytoplasmic tail. Survival occurs when recruited cytoplasmic adaptor proteins facilitate signal transduction through tumor necrosis factor receptor members such as TRAF6, which results in the release of nuclear factor κB (NF-κB) transcription activator. NF-κB regulates nuclear gene transcription to promote cell survival. Alternatively, programmed cell death occurs when TRAF6 and neurotrophin receptor interacting factor (NRIF) are both recruited to activate c-Jun N-terminal kinase (JNK); which phosphorylates c-Jun. The activated transcription factor c-Jun regulates nuclear transcription via AP-1 to increase pro-apoptotic gene transcription.
The corresponding monotherapy dosage of bicalutamide in the treatment of prostate cancer is 150 mg/day. Flutamide has also been employed as an antiandrogen in transgender women, with at least two treatment centers at one point reporting its frequent use. In the studies of nilutamide for transgender hormone therapy, the medication, given alone and not in combination with estrogen, induced observable signs of feminization in young transgender women (ages 19–33 years) within 8 weeks. These changes included breast development, decreased male-pattern hair, decreased spontaneous erections and sex drive, and positive psychological and emotional changes. Signs of breast development, such as increased nipple sensitivity, were, along with decreased male-pattern hair, the earliest indications of feminization, and occurred in all subjects within 6 weeks. Nilutamide by itself more than doubled luteinizing hormone (LH) and testosterone levels and tripled estradiol levels. The addition of 100 μg/day oral ethinylestradiol to nilutamide therapy after 8 weeks abolished the increase in LH, testosterone, and estradiol levels and dramatically suppressed testosterone levels, into the female or castrate range. On the basis of these results, both nilutamide alone, and particularly the combination of nilutamide and estrogen, were regarded as effective for producing antiandrogenic effects and feminization in transgender women.
Second Cup was founded in 1975 by Tom Culligan and Frank O'Dea in Toronto, Ontario. Culligan eventually purchased O'Dea's shares and expanded Second Cup into a 150-store chain. He sold it in 1988 to the founder of mmmuffins, Michael Bregman. As chairman and CEO, Khalil Al Gawad took Second Cup public in 1993. Between 1993 and 2002, it was owned by several American companies, including Coffee Plantation, Coffee People, and Caribou Coffee. Al Gawad sold Second Cup to Cara Operations Limited in 2002. In November 2006, Cara sold Second Cup to Dinecorp Hospitality, controlled by former Cara CEO Gabe Tsampalieros, who became chairman of Second Cup. Tsampalieros died on March 11, 2009. The trademark rights were subsequently split between Canada (the Second Cup Ltd.) and international (the Second Cup Coffee Company Inc.). Stacey Mowbray was head of the Canadian company, and Jim Ragas led the international side. Second Cup was featured in an episode of Undercover Boss that aired in March 2012 on the W Network. Under Mowbray's direction, Second Cup was presented as "a company that cares". In September 2012, the company launched Tassimo beverages. In April 2015, Second Cup started a rewards program, which allows users to earn points using a mobile app. Alix Box was the CEO and president at Second Cup Ltd. from 2014 until her sudden departure, in May 2017; she was temporarily replaced by Garry MacDonald. On April 12, 2018, Bregman announced an agreement with National Access Cannabis to develop and convert a network of recreational cannabis stores.
There was also honorary membership bestowed on those who had made unusual services to the Catholic faith, social or economic science, the arts, education, French culture generally, or to any other ideal of the association. 1967 membership 30,424; 1979 membership 26,000. Absorbed Foresters Franco Americains in 1939. The ACA went into rehabilitation in 2008 and later was liquidated. Most of its insurance policies were assumed by the Royal Arcanum.
Sources: en.wikipedia.org
Allergy/immunology Cardiology Cardiac electrophysiology Critical care medicine Endocrinology Gastroenterology Geriatrics Hematology/oncology Interventional cardiology Infectious diseases Nephrology Oncology Palliative care medicine Pulmonary Diseases Pulmonology Rheumatology Sleep medicine
==== Step 3: Capping ==== The capping step is performed by treating the solid support-bound material with a mixture of acetic anhydride and 1-methylimidazole or, less often, DMAP as catalysts and, in the phosphoramidite method, serves two purposes.
Methadone, sold under the brand names Dolophine and Methadose, among others, is a potent synthetic opioid used medically to treat chronic pain and opioid use disorder. Prescribed for daily use, the medicine relieves cravings and opioid withdrawal symptoms. Withdrawal management using methadone can be accomplished in less than a month, or it may be done gradually over a longer period of time, or simply maintained for the rest of the patient's life. While a single dose has a rapid effect, maximum effect can take up to five days of use. After long-term use, in people with normal liver function, effects last 8 to 36 hours. Methadone is usually taken by mouth and rarely by injection into a muscle or vein. Side effects are similar to those of other opioids. These frequently include dizziness, sleepiness, nausea, vomiting, and sweating. Serious risks include opioid abuse and respiratory depression. Abnormal heart rhythms may also occur due to a prolonged QT interval. The number of deaths in the United States involving methadone poisoning declined from 4,418 in 2011 to 3,300 in 2015. Risks are greater with higher doses. Methadone is made by chemical synthesis and acts on opioid receptors. Methadone was developed in Germany in the late 1930s by Gustav Ehrhart and Max Bockmühl. It was approved for use as an analgesic in the United States in 1947, and has been used in the treatment of addiction since the 1960s. It is on the World Health Organization's List of Essential Medicines.
IC50 / pIC50 values represent binding affinity only and do not reflect efficacy or pharmacokinetics, and some compounds listed are GABAA antagonists rather than agonists (e.g. flumazenil). Low IC50 or high pIC50 values indicate tighter binding (pIC50 of 8.0 = IC50 of 10nM, pIC50 of 9.0 = IC50 of 1nM, etc.) These are non subtype selective IC50 values averaged across all GABAA receptor subtypes, so subtype selective compounds with strong binding at one subtype but weak at others will appear unusually weak due to averaging of binding values (see e.g. CL-218,872) † indicates a predicted value from in silico modelling. Finally, note that the benzodiazepine core is a privileged scaffold, which has been used to derive drugs with diverse activity that is not limited to the GABAA modulatory action of the classical benzodiazepines, such as devazepide and tifluadom, however these have not been included in the list below. 2,3-benzodiazepines such as tofisopam are also not listed, as these act primarily as AMPA receptor modulators, and are inactive at GABAA receptors.
Sources: en.wikipedia.org
== Practical applications == With the human genome sequenced, the next step is the verification and functional annotation of all predicted genes and their protein products. Shotgun proteomics can be used for functional classification or comparative analysis of these protein products. It can be used in projects ranging from large-scale whole proteome to focusing on a single protein family. It can be done in research labs or commercially.
Due to their numerous sources indoors, concentrations of VOCs indoors are consistently higher (up to ten times higher) than outdoors. VOCs are emitted by thousands of indoor products. Examples include: paints, varnishes, waxes and lacquers, paint strippers, cleaning and personal care products, pesticides, building materials and furnishings, office equipment such as copiers and printers, correction fluids and carbonless copy paper, graphics and craft materials including glues and adhesives, permanent markers, and photographic solutions. Human activities such as cooking and cleaning can also emit VOCs. Cooking can release long-chain aldehydes and alkanes when oil is heated and terpenes can be released when spices are prepared and/or cooked. Cleaning products contain a range of VOCs, including monoterpenes, sesquiterpenes, alcohols and esters. Once released into the air, VOCs can undergo reactions with ozone and hydroxyl radicals to produce other VOCs, such as formaldehyde. Some VOCs are emitted directly indoors, and some are formed through the subsequent chemical reactions. The total concentration of all VOCs (TVOC) indoors can be up to five times higher than that of outdoor levels. New buildings experience particularly high levels of VOC off-gassing indoors because of the abundant new materials (building materials, fittings, surface coverings and treatments such as glues, paints and sealants) exposed to the indoor air, emitting multiple VOC gases.
== Related or interdisciplinary fields == Condensed matter physics, solid-state physics and solid-state chemistry Nanotechnology Mineralogy Supramolecular chemistry Biomaterials science Materials informatics
=== Wound healing === Because galectin-7 is mainly expressed in the stratified epithelia, it is considered a marker of the epidermis, oral cavity, cornea, esophagus, and anorectal epithelium tissues. The injury of corneal wounds causes an increase of sensitivity to receptors of galectin-7 in the cornea. The effect is then blocked by the beta lactose which suggests that the protein's CRD is involved in the stimulatory response to promote the closure of the wound. In a study conducted with mice where the galectin-7 protein was rendered non-functional, the mice were found to have delayed wound closure as the keratinocyte outgrowth was reduced. The study found that the protein localizes to podosomes, a surface in animals that is essential for cell migration and matrix remodeling, and affects the cortactin distribution. The cortactin is a protein that is widely distributed to cellular and in tissue structures which is correlated to the cell's morphology. This would suggest that the protein regulates actin-based lamellipodia formation, a form on the cell that drives cell migration. The kidney epithelial wound repair study found that a non-functional galectin-7 protein results in kidney epithelial cells having a shorter cilia and 33% reduced wound closure, found through various scratch tests. This all indicated how the galectin-7 protein also affects cilia structures and the wound healing process through simple epithelia. The uterine endometrial repair tests expressed how the protein is present and functional in late secretory and menstrual phases.
The dependence of osteosarcoma cells on NMNAT1-derived NAD for the PARP1-dependent DNA repair and survival is not restricted to cisplatin-treated cancer cells but has also been reported to occur in actinomycine D-treated tumor cell lines, as well. These data suggest that nuclear NAD synthesis by NMNAT1 may represent a therapeutic target in osteosarcoma and possibly in other tumors, as well.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.